Biomolecular engineer here, Mark. We're nervous man. The FDA seems to be giving up on regulatory control, so we expect pharma and biopharma will be beholden to EMEA and PMDA regulation a lot more in the coming years.

They should let that black dove fly. Sometimes it flies into the opponents net and that is a good